RBC Capital Maintains Sector Perform on Apogee Therapeutics, Raises Price Target to $135

RBC Capital analyst Brian Abrahams maintains Apogee Therapeutics (NASDAQ:APGE) with a Sector Perform and raises the price target from $97 to $135.